Depressive, negative and positive symptoms in schizophrenia: Response to different dosages of haloperidol

81 chronic schizophrenic in-patients during a riexacerbation phase, were included into the study. The patients were treated with HL from 1.50 to 18.00 mg p.o., t.i.d. No significant correlations were found among HRSD, SANS and SAPS. All the patients showed a significant amelioration at BPRS, HRSD, SAPS and SANS at the HL dosage below 0.2 mg/kg (<8.5 mg/die), while at the dosage up to 0.2 mg/kg (≤ 14.8 mg/die), they showed an amelioration only at BPRS and SAPS. Upper dosages of HL seem to show their efficacy on productive symptoms, while the efficacy on negative and depressive symptoms appeared only at lower dosages.